Last reviewed · How we verify
AZD5148
AZD5148 is a selective, potent and orally bioavailable adenosine A2A receptor antagonist.
AZD5148 is a selective, potent and orally bioavailable adenosine A2A receptor antagonist. Used for Multiple myeloma.
At a glance
| Generic name | AZD5148 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | adenosine A2A receptor antagonist |
| Target | A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AZD5148 works by blocking the action of adenosine at the A2A receptor, which is involved in the regulation of inflammation and immune responses. This blockade is thought to contribute to its therapeutic effects in various diseases.
Approved indications
- Multiple myeloma
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Headache
Key clinical trials
- Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody (PHASE2)
- Safety and Tolerability of AZD5148 in Japanese Participants (PHASE1)
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD5148 CI brief — competitive landscape report
- AZD5148 updates RSS · CI watch RSS
- AstraZeneca portfolio CI